Savara Pharmaceuticals
Repurposing vancomycin to fight drug-resistant infection in CF
This article was originally published in Start Up
Executive Summary
Savara Pharmaceuticals isn’t the first company keen to develop an inhaled version of a well-known antibiotic for treating lung infections in cystic fibrosis patients. But while other companies have developed inhaled forms of antibiotics against the relatively common infectious organism Pseudomonas aeruginosa, Savara is targeting an equally dangerous bug, methicillin-resistant Staphylococcus aureus.